key: cord-0935435-r14xwpm5
authors: Pineton de Chambrun, Marc; Frere, Corinne; Miyara, Makoto; Amoura, Zahir; Martin‐Toutain, Isabelle; Mathian, Alexis; Hekimian, Guillaume; Combes, Alain
title: High Frequency of Antiphospholipid Antibodies in Critically‐ill COVID‐19 Patients: a Link with Hypercoagulability?
date: 2020-06-12
journal: J Intern Med
DOI: 10.1111/joim.13126
sha: 66b6af90675301885544e656c2d0172740531efc
doc_id: 935435
cord_uid: r14xwpm5

Coronavirus disease 2019 (COVID‐19) is associated with both severe systemic inflammation and a prothrombotic state, as reflected by significant increases in fibrinogen and D‐dimers levels that have been associated with poor prognosis and high rates of severe pulmonary embolism. A recent report suggested a role for antiphospholipid antibodies (aPLA) in the thrombotic manifestations associated with severe COVID‐19. As we also recently noticed unexplained lengthening of activated partial thromboplastin time (aPTT) in some critically ill COVID‐19 patients, we explored our patients for aPLA positivity.

. All patients had refractory COVID-19-related ARDS requiring extracorporeal membrane oxygenation and were receiving non-fractioned heparin with a aimed aPPT ratio of 1. 

Clinical Characteristics of 138 Hospitalized Patients With

Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

EULAR recommendations for the management of antiphospholipid syndrome in adults

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome